Evogene Targets Acute Graft-Versus-Host Disease for AI Drug Discovery
Evogene announced a programme targeting acute graft-versus-host disease for AI-driven drug discovery.
Related stories
South Korean Shares Fall More Than 5% on AI Doubts
The KOSPI fell more than 5%, with shares set to end the month lower.
M impact | EQUITY | Oct 30, 2026, 02:44 AM UTC
Shenghong Technology H Shares Fall 15.1% as Q3 Net Profit Drops More Than Half
Shenghong Technology’s H shares fell as much as 15.1% early Friday after third-quarter net profit fell more than half year over year.
M impact | EQUITY | Oct 30, 2026, 02:34 AM UTC
Pond Group Q3 Operating Profit Rises 29.3% to 9 Billion Won
M impact | EQUITY | Oct 30, 2026, 02:33 AM UTC
Sanwa Holdings to Buy Back Up to 1.8% of Shares
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Vedanta Power Swings to Rs 83 Crore Q2 Profit as Revenue Climbs 38%
Revenue rose 38% year on year to Rs 2,908 crore, and net debt declined to Rs 7,444 crore.
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Coal India Q2 Profit Rises 53% as Revenue Reaches Rs 44,178.74 Crore
Revenue from operations rose to Rs 44,178.74 crore year on year. The board approved a second interim dividend of Rs 10.25 per share.
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC